These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38105625)

  • 41. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
    DeAngelo DJ; Yu D; Johnson JL; Coutre SE; Stone RM; Stopeck AT; Gockerman JP; Mitchell BS; Appelbaum FR; Larson RA
    Blood; 2007 Jun; 109(12):5136-42. PubMed ID: 17344466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
    Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
    Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
    Hartz B; Löbel U; Hagel C; Escherich G
    Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
    [No Abstract]   [Full Text] [Related]  

  • 44. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia.
    Shimony S; Liu Y; Valtis YK; Paolino JD; Place AE; Brunner AM; Weeks LD; Silverman LB; Vrooman LM; Neuberg DS; Stone RM; DeAngelo DJ; Luskin MR
    Blood Adv; 2023 Apr; 7(7):1092-1102. PubMed ID: 36508268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
    Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
    Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imaging Findings in Children Presenting with CNS Nelarabine Toxicity.
    Serrallach BL; Schafer ES; Kralik SK; Tran BH; Huisman TAGM; Wright JN; Morgan LA; Desai NK
    AJNR Am J Neuroradiol; 2022 Dec; 43(12):1802-1809. PubMed ID: 36328408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.
    Jain P; Kantarjian H; Ravandi F; Thomas D; O'Brien S; Kadia T; Burger J; Borthakur G; Daver N; Jabbour E; Konopleva M; Cortes J; Pemmaraju N; Kelly MA; Cardenas-Turanzas M; Garris R; Faderl S
    Leukemia; 2014 Apr; 28(4):973-5. PubMed ID: 24157581
    [No Abstract]   [Full Text] [Related]  

  • 48. Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial?
    Agrawal AK; Michlitsch J; Golden C; Hastings CA; Raphael R; Feusner JH
    J Clin Oncol; 2021 Feb; 39(6):694. PubMed ID: 33444071
    [No Abstract]   [Full Text] [Related]  

  • 49. Nelarabine: a new purine analog in the treatment of hematologic malignancies.
    Curbo S; Karlsson A
    Rev Recent Clin Trials; 2006 Sep; 1(3):185-92. PubMed ID: 18473971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nelarabine in the treatment of refractory T-cell malignant diseases.
    Kline J; Larson RA
    Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
    Commander LA; Seif AE; Insogna IG; Rheingold SR
    Br J Haematol; 2010 Aug; 150(3):345-51. PubMed ID: 20528871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
    Malone A; Smith OP
    Br J Haematol; 2017 Oct; 179(2):179-181. PubMed ID: 28891074
    [No Abstract]   [Full Text] [Related]  

  • 53. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
    Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia.
    Ghara N; Saha V
    Lancet Haematol; 2023 Jun; 10(6):e391-e393. PubMed ID: 37167993
    [No Abstract]   [Full Text] [Related]  

  • 55. Nelarabine use in leukemias.
    Kisor DF
    Drugs Today (Barc); 2006 Jul; 42(7):455-65. PubMed ID: 16894400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia.
    Pandey RK; DiPippo A; Kadia T; Pemmaraju N; Workeneh BT; Jabbour E; Ravandi F; Jain N
    Leuk Lymphoma; 2020 Nov; 61(11):2775-2777. PubMed ID: 32654562
    [No Abstract]   [Full Text] [Related]  

  • 57. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
    Candoni A; Lazzarotto D; Ferrara F; Curti A; Lussana F; Papayannidis C; Del Principe MI; Bonifacio M; Mosna F; Delia M; Minetto P; Gottardi M; Fracchiolla N; Mancini V; Forghieri F; Zappasodi P; Cerrano M; Vitale A; Audisio E; Trappolini S; Romani C; Defina M; Imbergamo S; Ciccone N; Santoro L; Cambò B; Iaccarino S; Dargenio M; Aprile L; Chiaretti S; Fanin R; Pizzolo G; Foà R
    Am J Hematol; 2020 Dec; 95(12):1466-1472. PubMed ID: 32777149
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine.
    Kawakami M; Taniguchi K; Yoshihara S; Ishii S; Kaida K; Ikegame K; Okada M; Watanabe S; Nishina T; Hamada H; Nakagawa M; Ogawa H
    Am J Hematol; 2013 Oct; 88(10):853-7. PubMed ID: 23757212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Frey NV; Luger SM
    Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
    Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
    Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.